Lyme Disease Treatment Reverses Alzheimer's Markers in First-of-its-Kind Study

HYDE PARK, N.Y. – April 27, 2026 – A groundbreaking case study published today in the peer-reviewed Journal of Alzheimer's Disease Reports provides the first clinical evidence that treating chronic Lyme disease can reverse key biological markers of Alzheimer's disease, offering a potential paradigm shift in how neurodegenerative conditions are understood and treated.

The study, led by veteran Lyme disease researcher Dr. Richard I. Horowitz, details the case of a 67-year-old woman whose validated blood markers for Alzheimer's disease normalized after a nine-week course of an oral antibiotic regimen. The findings lend powerful new support to the controversial hypothesis that underlying infections can be a primary driver of dementia, challenging long-standing clinical guidelines and opening new avenues for both research and patient care.

A Remarkable Reversal

The patient at the center of the study had a 15-year history of chronic Lyme disease and several associated co-infections. She presented with cognitive complaints and blood tests that revealed alarmingly high levels of phosphorylated tau (p-tau 217), a well-established biomarker indicating the presence of Alzheimer's pathology. Her p-tau 217 level was 0.33 pg/mL, more than double the normal threshold.

She underwent a nine-week protocol of double-dose dapsone combination therapy (DDDCT), a regimen developed by Dr. Horowitz that combines the antibiotic dapsone with a tetracycline, rifampin, azithromycin, and methylene blue, alongside nutritional support. The results were striking. After the treatment, her p-tau 217 level plummeted by 63% to 0.12 pg/mL, well within the normal range.

Furthermore, her amyloid beta 42/40 ratio—another crucial blood marker used to estimate future risk of cognitive impairment—showed significant improvement. The patient also reported subjective gains in her concentration, memory, and even joint flexibility.

"This research shows that when you target the underlying infectious and inflammatory drivers, the brain has a remarkable capacity for recovery," said Dr. Horowitz, Medical Director of the Hudson Valley Healing Arts Center, in a statement. With a 41-year career and over 13,000 Lyme patients treated, his work has consistently focused on the complex, multi-system nature of chronic illness. "The implications for millions of Americans living with both Lyme disease and cognitive decline could be significant based on this initial research."

The Infection-Alzheimer's Hypothesis Gains Ground

For decades, the dominant theory of Alzheimer's disease has centered on the accumulation of amyloid plaques and tau tangles in the brain. The idea that infections could play a causal role has long been on the scientific fringe, but it has been steadily gaining traction. This case study provides a powerful new piece of evidence for the "infection-amyloid-tau hypothesis."

This theory proposes that pathogens like the spirochetal bacterium Borrelia burgdorferi, which causes Lyme disease, can invade the brain and trigger a chronic inflammatory response. Some researchers even theorize that amyloid plaques themselves are part of an ancient antimicrobial defense system, forming to trap invading microbes. When this response becomes chronic, it can lead to the widespread neuronal damage characteristic of Alzheimer's.

Previous research supports this link. Studies have found Borrelia burgdorferi co-localized with amyloid plaques in the brain tissue of deceased Alzheimer's patients. Some epidemiological data has even suggested a more than tenfold increase in the incidence of Alzheimer's when spirochetal infections are detected. The National Institute on Aging (NIA) now acknowledges that infectious agents are among the environmental factors that can contribute to dementia, and has sponsored workshops to explore the connection.

A Challenge to Clinical Dogma

Despite the growing body of evidence, current clinical guidelines from major medical bodies like the Infectious Diseases Society of America (IDSA) and the American Academy of Neurology (AAN) do not recommend routine testing for Lyme disease in patients presenting with dementia. This stance is largely based on a lack of direct evidence showing that treating the infection can alter the course of the neurodegenerative disease.

Dr. Horowitz's case study directly confronts this gap. By using recently validated blood biomarkers, it provides the first direct clinical evidence that an antibiotic-based treatment for Lyme can normalize the very markers used to diagnose and track Alzheimer's. This creates what the study's authors call an "urgent case for further studies and updated clinical guidelines."

The diagnostic overlap between late-stage Lyme disease, known as neuroborreliosis, and other forms of dementia further complicates the picture. Both can cause memory loss, confusion, and cognitive decline, leading to potential misdiagnoses. The new findings suggest that a subset of patients currently diagnosed with Alzheimer's may have a treatable, underlying infectious cause for their symptoms.

The Dapsone Protocol: Promise and Complexity

The treatment at the heart of this study, Dapsone Combination Therapy (DCT), is itself an area of innovation and debate. Dapsone is an old antibiotic, primarily used for leprosy, that has potent anti-inflammatory effects and is uniquely effective against persistent, biofilm-forming bacteria that evade standard antibiotics. Dr. Horowitz has published ten studies on its use in chronic Lyme disease, consistently finding that cognitive improvement is the strongest documented outcome.

However, the therapy is not without risks. Dapsone can cause significant side effects, including anemia and nausea, and requires careful medical supervision and supplementation. The protocol used in the study was a complex cocktail of multiple agents designed to attack the Lyme bacteria and its co-infections from several angles.

While this case is a first for reversing Alzheimer's biomarkers by treating Lyme, the idea of using dapsone for Alzheimer's itself is not entirely new. An earlier Phase II trial in 2002 showed mixed results and was hampered by side effects in the elderly population. The success in this new case study may lie in its targeted approach: treating a patient with a confirmed chronic infection known to be susceptible to the drug regimen.

This single case, while not definitive proof, represents a pivotal moment. It provides a tangible link between treating a chronic infection and reversing the biological hallmarks of Alzheimer's disease, offering a powerful rationale for a new wave of research and a glimmer of hope for patients navigating the devastating intersection of infectious and neurodegenerative illness.